Progesterone stimulates pancreatic cell proliferation in vivo

A G Nieuwenhuizen, G A Schuiling, S M S Liem, H Moes, T R Koiter and J Th J Uilenbroek

Division of Reproductive Biology, Department of Obstetrics and Gynaecology, University of Groningen, Hanzeplein 1, NL-9713 GZ Groningen, The Netherlands and Department of Endocrinology and Reproduction, Erasmus University, Rotterdam, The Netherlands

(Correspondence should be addressed to A Nieuwenhuizen)

Abstract

Treatment of cyclic and pregnant rats with progesterone stimulates cell proliferation within the islets of Langerhans. It was investigated whether this effect of progesterone depends on sex and/or the presence of the gonads or the presence of oestradiol. For this purpose, Silastic tubes containing progesterone were inserted s.c. in intact and gonadectomized male and female rats, and in gonadectomized female rats treated with oestradiol. After 6 days of progesterone treatment, rats were infused for 24 h with 5-bromo-2'-deoxyuridine (BrdU) and dividing cells were identified in pancreatic sections by immunostaining for BrdU. Progesterone treatment increased islet-cell proliferation in intact male and female rats (P<0.05), but not in gonadectomized male and female rats or in gonadectomized female rats supplemented with oestradiol. Furthermore, in intact male and female rats, progesterone treatment also stimulated cell proliferation in extra-islet pancreatic tissue (P<0.05). Identification of the proliferating cells, by double-immunocytochemistry, revealed that progesterone treatment stimulated proliferation of both α and β cells within the pancreatic islets. In extra-islet pancreatic tissue, progesterone treatment stimulated proliferation in both duct (cytokeratin 20-immunoreactive) and non-duct cells. Progesterone treatment did not increase the number of single glucagon or insulin-containing cells outside the pancreatic islets, nor that of cytokeratin 20/insulin double-positive cells, suggesting that progesterone treatment did not stimulate differentiation of duct cells into endocrine cells. Progesterone treatment did not affect insulin responses to an i.v. glucose load (0.5 g/kg body weight). It is concluded that progesterone stimulates pancreatic cell proliferation indirectly; gonadal factor(s), not identical to oestradiol, is (are) probably involved.

Introduction

Treatment of cyclic female rats with progesterone increases plasma concentrations of progesterone and stimulates islet-cell proliferation, but does not affect glucose-stimulated insulin secretion in vivo (1). A stimulatory effect of progesterone treatment on pancreatic islet-cell proliferation was also observed in day-14 pregnant rats, but in these animals progesterone treatment did not result in increased plasma levels of progesterone, as these animals are able to maintain the plasma progesterone concentrations at the physiological level (1). Hence, it was suggested that the proliferative effect of progesterone treatment on the pancreatic islets might be indirect rather than direct (1). A direct effect of progesterone on the islets of Langerhans may be possible in intact female rats, as both the pancreatic α and β cells of these animals possess progesterone receptors (2, 3). Yet, a direct effect of progesterone on islet-cell proliferation is less likely in ovariectomized (OVX) rats, as ovariectomy causes loss of the progesterone receptors within the pancreatic islets; this loss can be prevented by oestradiol (E2) substitution (3). In male rats, a direct effect of progesterone seems unlikely as well, as the pancreas of male rats does not contain significant levels of progesterone receptors (4). The question whether the effect of progesterone on islet-cell proliferation may be direct or indirect was therefore investigated using both intact and gonadectomized male (TX) and OVX female rats, and also in E2-treated OVX rats. Islet-cell proliferation was assessed by the 5-bromo-2'-deoxyuridine (BrdU) method (5); the effects of progesterone treatment on extra-islet pancreatic tissue were studied as well. Proliferating cells were identified by immunostaining for either insulin, glucagon, synaptophysin (expressed selectively in neuroendocrine cells (6)) or the immunocytochemical marker of ductular epithelium, cytokeratin 20 (7). Finally, the effects of progesterone treatment on pancreatic islet function were investigated by i.v. glucose tolerance tests (IVGTTs).

Materials and methods

Animals

Male and female Wistar rats were used, aged 3–4 months and weighing 180–220 g. They were housed at 22±1 °C, with lights on from 0630 h until 1730 h, and
with water and food (Code 1062, Hope Farms, Woerden, The Netherlands) freely available.

To allow frequent stress-free sampling of blood from freely moving rats, a silicone cannula (internal diameter (ID) 0.5 mm, outside diameter (OD) 1.0 mm) was introduced via the right jugular vein under light ether anaesthesia, according to the method described by Steffens (8). On the same day, some of the animals’ ovaries/testes were removed under light ether anaesthesia; other rats were sham-operated. One group of O VX rats was continuously supplemented with E2 from 9 days after removal of the ovaries. Two Silastic implants (Dow Corning, Midland, MI, USA; length 1.5 cm, ID 1.47 mm, OD 1.96 mm) containing β-oestradiol (Sigma Chemical Co., St Louis, MO, USA) were implanted s.c. under light ether anaesthesia. This treatment establishes plasma E2 concentrations which are within the physiological range (9).

**Progesterone treatment**

Fourteen days after implantation of the cannula and gonadectomy, progesterone was administered continuously for 7 days by means of three Silastic tubes (length 3.8 cm, ID 3.35 mm, OD 4.64 mm) containing crystallized progesterone which were implanted s.c. under light ether anaesthesia. Control animals received three identical but empty implants. This resulted in ten experimental groups: control intact female rats (n=7), progesterone-treated intact female rats (n=7), control OVX rats (n=5), progesterone-treated OVX rats (n=5), control OVX rats treated with E2 (n=5), progesterone-treated OVX rats treated with E2 (n=7), control intact male rats (n=5), progesterone-treated intact male rats (n=5), control TX rats (n=5) and progesterone-treated TX rats (n=6). After 6 days of continuous progesterone treatment IVGTTs were carried out as described previously (10). In short: at 1100 h the rats received a glucose injection (0.5 g/kg body weight, dissolved in saline) via the cannula in the right atrium. Blood samples (0.4 ml) were withdrawn 11 and 1 min before and 2, 5, 10, 15, 20, 30 and 45 min after injection. Immediately after completion of the IVGTT, rats were infused for 24 h with BrdU (Boehringer Mannheim GmbH, Mannheim, Germany) dissolved in saline (1.2 mg BrdU/h), for visualization of pancreatic cell proliferation. After 24 h BrdU infusion and 7 days of progesterone treatment, rats were killed by aortic puncture under deep ether anaesthesia and the pancreas was removed, divided into head and tail, subsequently snap-frozen in isopentane and stored at −70°C until sectioning.

**Pancreatic cell proliferation**

Cryostat sections (4 μm) were immunostained for BrdU-positive cells as previously described (5). In brief, frozen sections were fixed with Carnoy (ethanol, chloroform, glacial acetic acid; 6:3:1) and incubated for 60 min with a monoclonal antibody directed against BrdU (kindly donated by Dr L F M H de Leij, Department of Immunology, University of Groningen). Subsequently, they were incubated for 15 min with a peroxidase-conjugated rabbit anti-mouse antibody. BrdU-positive cells were stained by the use of 3-amino-9-ethyl-carbazole (AEC). Finally, slides were counterstained with Celestine blue and Mayer’s haematoxylin.

Per animal pancreatic cell proliferation was determined in one head and one tail section. Cell proliferation within the pancreatic islets was determined by counting all BrdU-positive and BrdU-negative islet cells from randomly chosen islets; at least 1000 islet cells of each animal were counted. Also, in these pancreatic sections cell proliferation in extra-islet tissue was determined. For this, in each section the total number of BrdU-positive cells in extra-islet tissue of six randomly chosen areas (0.79 mm² each) was counted.

**Cell identification**

In intact female rats, in which the present progesterone treatment has previously been shown to stimulate islet-cell proliferation (1), BrdU-positive cells were identified using double-staining for BrdU and insulin, glucagon, cytokeratin 20 (expressed in ductular epithelium) or synaptophysin (expressed in neuro-endocrine cells). After fixation in paraformaldehyde (4%) and incubation with 20 μg/ml protease K (Boehringer Mannheim) for 30 min, sections were incubated for 60 min with either a guinea pig polyclonal antibody directed against bovine insulin, a mouse antibody against rat glucagon, a mouse antibody against human cytokeratin 20 (Dako, Glostrup, Denmark), or a mouse antibody against synaptophysin (Dako). Subsequently, they were incubated for 30 min with either a peroxidase-conjugated rabbit anti-guinea pig antibody (insulin) or a phosphatase-conjugated rabbit anti-mouse antibody (glucagon, cytokeratin 20, synaptophysin). Immunoreactive cells were stained by the use of 3,3′-diaminobenzidine (DAB) (insulin) or Fast Red (Sigma) (glucagon, cytokeratin 20, synaptophysin). This was followed by BrdU staining. Within the islets of the pancreatic sections, the percentage BrdU-positive cells which also stained positive for insulin or glucagon was determined. Islets were defined as cell clusters containing more than two
adjacent insulin-, glucagon- or synaptophysin-positive cells. Furthermore, in extra-islet tissue of six randomly chosen areas (0.79 mm² each) the percentage BrdU-positive cells which also stained positive for insulin, glucagon, synaptophysin or cytokeratin 20 was determined. In these areas also the incidence of single insulin and glucagon immunoreactive cells was determined. In the pancreatic sections double-stained for cytokeratin 20 and insulin, the number of cytokeratin 20/insulin double-immunoreactive cells was determined in extra-islet tissue of ten randomly chosen areas (0.79 mm² each).

**Determination of glucose, insulin, progesterone, 20α-dihydroprogesterone and E2**

Plasma glucose concentrations were measured in diluted plasma samples by the glucose-oxidase/peroxidase method (GOD-Perid, Boehringer Mannheim). Plasma insulin concentration was determined by double-antibody RIA using a guinea pig antibody against bovine insulin, a rat standard (batch no. 220891, NOVO Nordisk, Bagsvaerd, Denmark), and a donkey anti-guinea pig antibody coated on cellulose particles (SAC-CEL ASAC 3, Immuno Diagnostics, Boldon, UK). Bovine insulin (NOVO Nordisk) was iodinated at the Isotope Laboratory of the Groningen University Hospital, and used as tracer. Plasma progesterone, 20α-dihydroprogesterone (20α-hydroxy-4-pregn-3-one (20α-OHP)) and E2 levels were determined after 6 days of progesterone treatment by RIA, carried out at the Isotope Laboratory of the Groningen University Hospital (progesterone and E2; Dr J J Pratt) and the Department of Endocrinology and Reproduction of the Erasmus University, Rotterdam (20α-OHP; Dr J Uilenbroek).

**Parameters and statistics**

Glucose tolerance during the i.v. glucose load was evaluated using the glucose disappearance constant (Kg) calculated as the slope of the least-square regression line relating the natural logarithm of the glucose concentration to time between 5 and 15 min, expressed as %/min (11). For the insulin responses to the i.v. glucose load, the areas under the curves (AUC) were calculated from 0 to 15 min after glucose injection. Data are expressed as mean±S.E.M. Statistical comparisons were made by a Mann–Whitney U test. A level of random difference of P<0.05 was considered significant.

**Results**

**Plasma concentrations of progesterone, 20α-OHP and E2**

Plasma concentrations of progesterone (Fig. 1a) and 20α-OHP (Fig. 1b) were lower in gonadectomized rats and in male rats when compared with intact female rats not treated with progesterone. In all experimental groups, plasma concentrations of progesterone and 20α-OHP were increased after 6 days of progesterone treatment. In non-progesterone treated O VX rats, E2 supplementation increased plasma E2 concentrations (0.72±0.12 nmol/l vs not detected). Progesterone treatment for 6 days did not affect plasma E2 levels in E2-supplemented OVX rats (0.96±0.22 vs 0.72±0.12 nmol/l, not significant (NS)).

**Pancreatic cell proliferation**

Within the pancreatic islets Figure 2a shows that the rate of cell proliferation within the pancreatic islets was identical in all non-progesterone treated rats, male or female, intact or gonadectomized and whether or not supplemented with E2. Progesterone treatment for 7 days increased islet-cell proliferation in intact female and male rats. In gonadectomized rats, however, whether or not supplemented with E2, progesterone treatment did not affect islet-cell proliferation.

Outside the pancreatic islets In female rats, ovariectomy per se increased the rate of cell proliferation in extra-islet pancreatic tissue (Fig. 2b); this increased rate of extra-islet cell proliferation was suppressed by E2 supplementation. In (non-progesterone treated) intact male rats, cell proliferation rates of extra-islet pancreatic tissue were higher than in (non-progesterone treated) female rats; moreover, in contrast to female rats, castration did not affect cell proliferation in extra-islet pancreatic tissue in male rats. Furthermore, progesterone treatment for 7 days stimulated cell proliferation of extra-islet pancreatic tissue in both intact female and male rats, but was without effect in any group of gonadectomized rats.

**Identification of proliferating cells**

Within the pancreatic islets In intact female rats not treated with progesterone, 79.8±10.6% of all BrdU-positive cells within the pancreatic islets contained immunoreactive insulin, while 17.0±4.4% of all BrdU-positive cells contained immunoreactive glucagon. After 7 days of progesterone treatment these percentages were 72.9±3.7 and 18.6±1.9%, respectively. The effects of progesterone were not statistically significant.

Outside the pancreatic islets In intact female rats not treated with progesterone, the incidence of insulin-immunoreactive cells in extra-islet pancreatic tissue was 1.6±0.1 cells/mm², and that of glucagon-immunoreactive cell 2.8±0.2 cells/mm². In progesterone-treated female rats, the incidence of insulin-immunoreactive cells in extra-islet pancreatic tissue was unaffected (1.3±0.2 cells/mm², NS), but the incidence of glucagon-immunoreactive cells was diminished.
(1.6±0.2 cells/mm²,  \( P<0.05 \)) when compared with female rats not treated with progesterone.

Figure 3 shows pancreatic sections, double-stained for BrdU and cytokeratin 20, of intact female rats after 7 days of sham treatment (Fig. 3a) or after 7 days of progesterone treatment (Fig. 3b). In extra-islet pancreatic tissue of intact female rats, progesterone treatment increased the incidence of cytokeratin 20/BrdU double-positive cells (13.0±1.1 vs 1.9±0.7 cells/mm²,  \( P<0.05 \)). Also, the number of cytokeratin 20-negative/BrdU-positive cells increased (35.6±2.7 vs 5.0±1.5 cells/mm²,  \( P<0.05 \)), so that the percentage cytokeratin 20-positive cells within the BrdU-immunoreactive population was similar in progesterone-treated and non-progesterone treated female rats (26.8±0.9 vs 24.2±6.9%, NS). The number of insulin/BrdU, glucagon/BrdU and synaptophysin/BrdU double-positive cells was very low in non-progesterone treated female rats: only 0.4±0.2% of the BrdU-positive cells also stained positive for glucagon, while no BrdU-positive cells were also positive for insulin or synaptophysin. After 6 days of progesterone treatment, 0.4±0.2% of the BrdU-positive cells also stained positive for insulin, but in these animals no BrdU-positive cells also stained positive for glucagon or synaptophysin.

Figure 4 shows a pancreatic section of an intact female rat, not treated with progesterone, double-stained for insulin and cytokeratin 20. In intact female rats not treated with progesterone, the incidence of cytokeratin 20/insulin double-immunoreactive cells in pancreatic tissue was 0.18±0.06 cells/mm². In progesterone-treated female rats, this incidence was 0.31±0.10 cells/mm² (NS).

**IVGTT**

Glucose tolerance Glucose tolerance, calculated as the  \( K_c \), was not affected by progesterone treatment in any experimental group: 4.3±0.2 vs 4.4±0.2%/min in intact female rats, 3.8±0.3 vs 3.8±0.4%/min in OVX rats, 4.4±0.2 vs 4.2±0.1%/min in E2-supplemented OVX rats, 4.0±0.1 vs 4.3±0.1%/min in intact male

---

**Figure 1** Plasma concentrations of progesterone (a) and 20\( \alpha \)-OH (b) in intact female, OVX, E2-supplemented OVX (OVX+E2) and intact and TX male rats after 6 days of treatment with progesterone-containing (solid bars) and empty (open bars) implants. The symbols # and * denote statistically significant differences (\( P<0.05 \)) when compared with non-progesterone treated intact female rats, and to the appropriate non-progesterone treated controls respectively. ND, not detected (<0.5 ng/ml). In each group, \( n=5–7 \).
rats, and 3.7±0.2 vs 3.9±0.3%/min in TX rats (for all groups: NS).

**Insulin responses** In intact female rats, after 6 days of progesterone treatment, baseline plasma insulin levels were increased when compared with non-progesterone treated female rats (3.9±0.5 vs 2.3±0.3 ng/ml, *P*< 0.05). In all other experimental groups, progesterone treatment did not affect baseline plasma insulin levels.

Progesterone treatment for 6 days did not affect plasma insulin responses to an i.v. glucose challenge, as calculated as AUC, in any experimental group: 79±19 vs 54±5 ng/ml min in intact female rats, 69±20 vs 74±16 ng/ml min in OVX rats, 94±6 vs 80±14 ng/ml min in E2-supplemented OVX rats, 61±15 vs 71±12 ng/ml min in intact male rats, and 83±6 vs 66±8 ng/ml min in castrated male rats (for all groups: NS).

**Discussion**

Progesterone treatment stimulated islet-cell proliferation in both intact male and female rats, although only female rats possess significant amounts of pancreatic progesterone receptors (2–4). Moreover, the effect of progesterone on islet-cell proliferation was absent in TX male and OVX female rats, suggesting that the gonads play an essential role in the genesis of the proliferative effect of progesterone. Yet, it cannot be excluded that progesterone has an effect also in TX rats, but that this effect is masked by the large variations in cell proliferation rates in both control and progesterone-treated TX rats. In OVX rats, the absence of an effect of progesterone on islet-cell proliferation might be explained by the loss of progesterone binding sites within the pancreatic islets after ovariectomy (3). However, although E2 treatment may prevent the loss of progesterone receptors after ovariectomy (3), it did not prevent the loss of the stimulatory effect of progesterone on islet-cell proliferation. It, therefore, appears that in both male and female rats the effect of progesterone treatment on islet-cell proliferation is not mediated by progesterone receptors within the islets. Rather, the effect of progesterone treatment is indirect and, as the effect disappears after gonadectomy, is mediated by (some) gonadal factor(s). The involvement
of these gonadal factor(s) might also explain the discrepancy between the stimulation of islet-cell proliferation by progesterone in vivo, as shown in the present study, and the inhibitory effects of progesterone on islet-cell proliferation in vitro (12–14), under which conditions such factors are absent.

Clearly, E2 does not represent the above mentioned gonadal factor, as E2 administration did not restore the proliferative effect of progesterone in OVX rats. Previously, we suggested that increased levels of another ovarian steroid, 20α-OHP, which can be synthesized from progesterone by the ovaries (15), might be involved in the stimulation of islet-cell proliferation by progesterone treatment (1). However, the present results show that in the progesterone-treated gonadectomized rats high levels of 20α-OHP do not correspond with increased cell proliferation. Next to steroids, the gonads of the male and the female produce and secrete appreciable amounts of all kinds of growth factors, such as activin and inhibin (16, 17), members of the transforming growth factor-β superfamily of growth factors, which generally inhibit pancreatic cell replication (18, 19), and the insulin-like growth factors-I and -II (20–22), which are capable of stimulating pancreatic islet-cell proliferation (23). Moreover, in human testis (24) and ovary (25) a growth hormone/placental lactogen variant is produced which also might stimulate cell proliferation in pancreatic tissue (cf. 26, 27). Modulation of the secretion of these growth factors...
may be involved in the stimulation of pancreatic cell proliferation by progesterone treatment.

The present study shows that the effect of progesterone on cell proliferation is not limited to the pancreatic islets (1). Also in extra-islet pancreatic tissue cell proliferation was stimulated after treatment with progesterone. This agrees with the increased pancreatic mass after progesterone treatment, as described previously (28). Perhaps the stimulatory effect of progesterone treatment on cell proliferation within the pancreas should be seen in the light of earlier observations that progesterone is able to stimulate cell proliferation in many other tissues, such as uterus, oviduct and mammary gland (29). Furthermore, the effect of progesterone on pancreatic cell proliferation does not seem to be restricted to a single cell type. Thus, in extra-islet pancreatic tissue, double-immunostaining revealed that there was increased proliferation of ductular (i.e. cytokeratin 20-immunoreactive) cells, although these cells were not preferably stimulated by progesterone, as the relative contribution of ductular epithelium to the total number of cell replications in extra-islet pancreatic tissue did not increase. We did not detect any proliferating synaptophysin-immunoreactive (i.e. neuro-endocrine (6)) cells in non-islet pancreatic tissue. Hence, progesterone treatment stimulated cell proliferation in other cell types present in extra-islet pancreatic tissue, of which by far the most abundant are acinar cells (30, 31).

Within the islets themselves, in intact female rats, the ratio of proliferating α and β cells remained constant after progesterone treatment, suggesting that progesterone stimulated the proliferation of both cell types to the same extent. Besides replication of existing α and β cells, new islet (α and β) cells can also be formed by differentiation from stem cells present within the ductal epithelium of the adult rat pancreas (32–35). Still, in the present study there were no signs of increased islet-cell proliferation, at least during pregnancy (42) and in diabetic db/db mice (43), hyperphagia does not seem to be the general mechanism underlying the increased islet-cell proliferation following progesterone treatment. Furthermore, progesterone treatment did not affect the insulin responses to glucose in any experimental group.

The stimulatory effect of progesterone treatment on proliferation of pancreatic cells, including β-cells, appears not to be reflected by an increase in insulin secretion. Therefore, at first sight, the physiological significance of the seemingly unspecific effect of progesterone on pancreatic cell proliferation remains undefined. It is suggested that, in the female, progesterone may prepare the pancreas for increased activity during reproduction by stimulating cell proliferation (10, 37–39). For the expression of this effect of progesterone, gonadal factor(s) play(s) an essential role.

Acknowledgements

We would like to thank Ms G C J van der Schaaf-Verdonk and Ms N Valkhof for their technical assistance, and Dr R S B Liem (Laboratory for Cell Biology and Electron Microscopy, University of Groningen) for performing the microphotography.

References
